ExpertiseUpdated on 21 May 2026
Oligodendrocyte biology and remyelination platform
business developer BIOMED at Health Campus Limburg DC
About
Are you developing new therapies for neurodegenerative disease that target oligodendrocyte biology or de- and remyelination?
▶ Progress your development programs faster by building on our expertise glial cell biology, neuroscience, and lipid metabolism.
▶ Our validated models are continuously exploited in proprietary research programs and service activities for the private sector.
▶ We are keen on creating collaborative and longlasting partnerships by meeting rapidly changing needs and requirements in a flexible way and delivering on our promises.
POSSIBLE APPLICATIONS
• Test the therapeutic activity of candidate therapies on oligodendrocyte biology and remyelination in vitro at three levels: differentiation and proliferation of oligodendrocyte precursor cells (OPCs), migration behaviour of OPCs and axon-wrapping potential. Multiple conditions can be tested in parallel.
• Test the effect of therapies in a more complex multicellular brain environment using ex vivo in brain slice cultures. Multiple conditions can be tested in parallel.
• Test your candidate therapies in in vivo models which includes a battery of functional, structural, and clinical outcome measures.
Attached files
Organisation
Similar opportunities
Expertise
Blood-Brain Barrier in vitro to in vivo models
An Voets
business developer BIOMED at Health Campus Limburg DC
Partnership
α-Synuclein-Degrading Catalytide for Parkinson’s Disease (in vivo validated)
- Joint development
Toshifumi Akizawa
CEO at O-Force Co., Ltd.